POS0025 PREVALENCE OF ATTENTION DEFICIT HYPERACTIVITY DISORDER AMONG ADULT PATIENTS WITH FIBROMYALGIA
Authors: S. Moyano, W. Berrios, I. Gandino, E. Soriano, J. Rosa
Journal: Annals of the Rheumatic Diseases (2022)

Background Fibromyalgia (FM) and attention deficit hyperactivity disorder (ADHD) share some clinical features, and a reduced dopamine function has been proposed for both disorders. ADHD is a chronic condition, marked by persistent inattention, impaired concentration, hyperactivity, impulsivity, emotional lability, anxiety and disorganized behaviour. High rates of comorbidity between ADHD and FM have been reported, as well as some evidence that patients with both conditions experience heightened disease severity. Objectives Our purpose was to determine the prevalence of ADHD symptoms in patients with FM and to assess the relationship with disease impact. Methods Consecutive patients, older than 18 years, with diagnosis of FM (ACR 2016 criteria) without known cognitive impairment, seen at the Rheumatology Unit between April 2018 and December 2019, were included. At inclusion visit the collected data included Revised Fibromyalgia Impact Questionnaire (FIQ-R) and Health Assessment Questionnaire, Argentine version (HAQ-A). During the Neurology visit, the following tests were performed: Montreal Cognitive Assessment (MoCA) test for evaluating the presence of cognitive impairment, Conners Continuous Performance Test II (CPT II) for the assessment of ADHD, and Wender-Utah Rating Scale (WURS) to retrospectively assess childhood ADHD symptoms. Univariate analysis was performed using t-tests for normally distributed continuous variables, and Wilcoxon rank sum test for non-normally distributed continuous variables. A chi-square or Fisher test was used when appropriate for categorical variables. Predictors that were found to be related to ADHD (p ≤ 0.20) were then entered into a multivariable logistic regression model. Results 60 patients with FM and 71 matched controls without FM or known cognitive impairment were included. FM patients’ characteristics are shown in Table 1. 61.7% (n=37) of the patients with FM tested positive for adult ADHD. In 48.6% (18/37) of them, the diagnosis had been missed in childhood. Participants with both FM and a positive adult ADHD screening test did not score significantly higher on the FIQ-R (52.3, SD= 16.1 vs. 47.9, SD= 12.3; p= 0.2693) and HAQ-A (0.693, SD= 0.455 vs. 0.521, SD= 0.428; p=0.1523) compared with patients without ADHD. Retrospectively assessed childhood ADHD was significantly associated with adult persistence (OR 55.1, CI=3.6 to 842.6, p=0.004). Table 1. Clinical and demographic characteristics of patients with FM. Characteristics n=60 Female, n (% ) 53 (88.3) Age (years), mean (SD ) 58.3 (14.2) Time from diagnosis (years), mean (SD ) 5.2 (5) Scholarity (years), mean (SD ) 12.9 (3.4) HAQ-A, mean (SD ) 0.627 (0.449) FIQ-R, mean (SD ) 50.6 (14.8) Cognitive complaint, n (% ) 34 (56.7) Depression, n (% ) 35 (58.3) Anxiety, n (% ) 27 (45) Concomitant personality disorders 39 (65) Patients with FM had significantly higher prevalence of cognitive impairment (43.3% vs. 16.9%; p&lt;0.0001), childhood ADHD symptoms (31.7% vs. 14.1%; p=0.016) and adult ADHD symptoms (61.7% vs. 23.9%; p&lt;0.0001) than the control group (Figure 1). Figure 1. Percentage of FM patients with cognitive impairment, childhood and adult ADHD. Comparison with the control population. Conclusion The co-occurrence of adult ADHD in FM was highly prevalent. In nearly half of the patients the diagnosis had been overlooked during childhood and it was associated with adult persistence. The prevalence of cognitive impairment, and childhood and adult ADHD was higher in patients with FM compared with the control group. ADHD was not associated with the FM impact. Evaluation of ADHD symptoms in patients with FM is important for recognition and treatment of this comorbidity. References [1]Stefano P et al. J Psychiatr Res. 2021 Apr;136:537-542. [2]Karas H et a.l Int J Psychiatry Clin Pract. 2020 Sep;24(3):257-263. [3]Kessler RC et al. Biol Psychiatry. 2005 Jun 1;57(11):1442-51. Acknowledgements The authors thank the patients who agreed to participate in this study. Disclosure of Interests None declared